Please wait...
GulfBase Live Support
Leave a message and our representative will contact you soon
- US govt shutdown sends airlines scrambling as travel chaos looms
- NBK wins award of GCC Excellence for Energy Efficiency in Buildings in 2025
- QSE index closes higher
- Gold price in Qatari market decline by 0.40% this week
- Nasdaq Dubai welcomes Binghatti Holding's debut $500m Green Sukuk
- Adnoc Distribution invests $300m yearly in region
- IHC says no plans to sell stake in Aldar Properties
- Aramex resumes deliveries to Syria after ten-year pause
- Parkin posts record Q3, sees better full-year growth on strong revenues
- Qatari firm to invest $29.7 billion in Egypt coastal development
16/09/2025 07:55 AST
Jamjoom Pharmaceuticals Factory Company (Jamjoom Pharma), one of the fastest-growing pharmaceutical companies in the Middle East and Africa, has signed a strategic commercialisation agreement with Bio-Thera Solutions, a global biopharmaceutical company specialising in innovative therapies and biosimilars.
Under the agreement, Jamjoom Pharma will obtain the exclusive rights to commercialise BAT2306 - a proposed biosimilar to Novartis' Cosentyx (secukinumab) - across the Middle East and North Africa (MENA) region.
Cosentyx is a biologic medication used to treat conditions like psoriasis, psoriatic arthritis, and ankylosing spondylitis.
Jamjoom Pharma will manage regulatory submissions, market access, and commercialisation in MENA, while Bio-Thera will oversee product development and global manufacturing from its state-of-the-art facilities in Guangzhou, China.
"This collaboration is a strategic milestone for Jamjoom Pharma and a testament to our mission of broadening access to advanced biologics in the MENA region," said Tarek Hosni, Chief Executive Officer of Jamjoom Pharma. "By joining forces with Bio-Thera, we are combining world-class biosimilar development with Jamjoom's deep regional expertise, strong commercial capabilities, and commitment to delivering high-quality, affordable therapies. This agreement strengthens our leadership in the biopharmaceutical sector and reinforces our role as a trusted partner in improving patient outcomes."
"Bio-Thera is committed to bringing affordable medicines to patients in need around the world, " said Bert Thomas, Senior Vice President of Business Development.
"Partnering with JamJoom Pharma to bring BAT2306 to patients in the MENA region is a demonstration of that commitment. We are proud to partner with Jamjoom Pharma and look forward to a successful collaboration," Thomas said.
Trade Arabia
| Ticker | Price | Volume |
|---|
| Ticker | Price | Change |
|---|---|---|
| SPIMACO | 30.88 | 0.88 (2.93 |
| AVALONPHARMA | 127.10 | 0.10 (0.07 |
07/11/2025
In a new achievement that confirms its leadership in adopting the highest sustainability standards, National Bank of Kuwait building won the award of Best Financial Building as part of the GCC Excell
Kuwait Times
07/11/2025
Adnoc Distribution Chief Executive Officer Bader Al Lamki said the company earmarks between $250 million and $300 million annually to support organic growth across the three countries where it operat
Trade Arabia
07/11/2025
IHC, the Abu Dhabi headquartered global investment company focused on building dynamic value networks, on Thursday reaffirmed that it does not intend to pursue the sale of its shareholding in Aldar P
Trade Arabia
07/11/2025
Aramex has resumed parcel and freight deliveries to Syria as of 15 September 2025, officially ending a suspension that lasted more than ten years. The move marks a major step in rebuilding trade rout
Gulfnews
07/11/2025
Parkin Company PJSC, Dubai's largest provider of paid public parking, reported record third-quarter results, with revenues up 43% year-on-year to Dh343.3 million, driven by higher tariffs, network ex
Gulfnews
Financial Information Co.
P.O. Box 69410, Jeddah 11547, Saudi Arabia